3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
139
NIH
58
NETWORK
46
INDUSTRY
38
UNKNOWN
1
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
1
Interventions
fludarabine
5
Cyclophosphamide
5
Azacitidine
4
Cytarabine
3
venetoclax
2
pegylated granulocyte colony-stimulating factor
2
bisantrene
2
Metformin
2
Etoposide
2
Dasatinib
2
Clofarabine
2
Busulfan
2
vosaroxin
1
treosulfan
1
peginterferon alfa-2a
1
nilotinib
1
liposomal amphotericin B
1
fludarabine phosphate
1
defactinib
1
decitabine and cedazuridine drug combination
1
cedazuridine
1
cc-486
1
aldesleukin
1
Zinc Sulfate
1
Zinc
1
Vitamin D
1
Urination
1
Tranexamic Acid
1
Thiotepa
1
Thalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Daunorubicin
×
Other hematologic neoplasm
×
Clear all
NCT02416388
2024-08-07
BIG-1
University Hospital, Angers
Phase 2/3
Recruiting
3,100 enrolled